Share This Article:

Chinese Herbal Medicine Combined Conventional Chemotherapy Regimens in Advanced Recurrent Breast Mammary Carcinoma

Abstract Full-Text HTML Download Download as PDF (Size:1375KB) PP. 1506-1512
DOI: 10.4236/jct.2013.410182    3,867 Downloads   5,187 Views  

ABSTRACT

Purpose: Aiming at starting the ball rolling and contributing humble effort to promoting traditional Chinese medicine, we report one successful case of GP regimen of combining chemotherapy with traditional Chinese medicine decoction (lung description) for breast cancer with lung and bone metastases. Patients and Methods: A second-line chemotherapy regimen of GP (cisplatin + gemcitabine) was applied. In the meantime, we administered Chinese herbal medicine (Fei Decoction, mixed with a variety of effective herbal components) to help her recover from the poor condition. Results: The tumor markers (CEA, CA15-3) had dramatically decreased to the normal range. Both lung and bone metastatic sites reduced according to CT and ECT imaging, and this patient felt free from the complaint of pulmonary and cardiac discomfort. The quality of life has been greatly improved, and the PFS (Progression-Free-Survival) and TTP (Time-to-Progression) have been prolonged from the onset to date. Conclusions: In the course of this combined treatment, it has been shown that Chinese herbal medicine played an important role in the therapy of breast mammary carcinoma. Therefore, Chinese herb may turn out to be an additional choice with its better benefits and tolerability in the treatment of recurrent breast mammary carcinoma.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

M. Hu, R. Chen, L. Zhu, C. Tao, T. Wang, X. Xia, P. Li, Y. Gong and G. Lv, "Chinese Herbal Medicine Combined Conventional Chemotherapy Regimens in Advanced Recurrent Breast Mammary Carcinoma," Journal of Cancer Therapy, Vol. 4 No. 10, 2013, pp. 1506-1512. doi: 10.4236/jct.2013.410182.

References

[1] W. Chen, R. Zheng, S. Zhang, P. Zhao, G. Li, L. Wu and J. He, “Report of Incidence and Mortality in China Cancer Registries,” Chinese Journal of Cancer ResearchRes, Vol. 25, No. 1, 2013, pp. 10-21.
[2] Z. L. Tang, J. Bai, L. N. Gu, L. Li and D. Xue, “A Systematic Review: Epidemic Status of Prostate Cancer and Breast Cancer from 2000 to 2010 in China,” China Cancer, Vol. 22, No. 4, 2013, pp. 260-265.
[3] T. Qin, Z. Yuan, R. Peng, B. Bai, Y. Shi, X. Teng, et al., “HER2-Positive Breast Cancer Patients Receiving Trastuzumab Treatment Obtain Prognosis Comparable with that of HER2-Negative Breast Cancer Patients,” Journal of OncoTargets and Therapy, Vol. 9, No. 6, 2013, pp. 341-347. http://dx.doi.org/10.2147/OTT.S40851
[4] X. Li, G. Y. Yang, X. X. Li, Y. Zhang, J. L. Yang, Chang. J, et al., “Bensoussan A. Traditional Chinese Medicine in Cancer Care: A Review of Controlled Clinical Studies Published in Chinese,” Plos One, Vol. 8, No. 14, 2013, pp. 1-11.
[5] K. K. Chan, T. J. Yao and B. Jones, “The Use of Chinese Herbal Medicine to Improve Quality of Life in Women Undergoing Chemotherapy for Ovarian Cancer: a Doubleblind Placebo-Controlled Randomized Trial with Immunological Monitoring,” Annals of Oncology, Vol. 22, No. 10, 2011, pp. 2241-2249. http://dx.doi.org/10.1093/annonc/mdq749
[6] M. Jiang, J. Yang, C. Zhang, B. Liu, K. Chan and H. Cao, “Clinical Studies with Traditional Chinese Medicine in the Past Decade and Future Research and Development,” Planta Med, Vol. 76, No. 17, 2010, pp. 2048-2064. http://dx.doi.org/10.1055/s-0030-1250456
[7] E. Ernst, “Complementary and Alternative Medicine (CAM) and Cancer: the Kind Face of Complementary Medicine,” International Journal of Surgery, Vol. 7, No. 6, 2009, pp. 499-500. http://dx.doi.org/10.1016/j.ijsu.2009.08.005
[8] Q. J. Wang, W. X. Zhu and X. M. Xing, “Analysis of the Incidence and Survival of Female Breast Cancer in Beijing during the Last 20 Years,” Chinese Journal of Oncology, Vol. 28, No. 3, 2006, pp. 208-210.
[9] W. Q. Chen, S. W. Zhang, R. S. Zheng, H. M. Zeng, X. N. Zhou, P. Zhao, et al., “Report of Cancer Incidence and Mortality in China, 2009,” China Cancer, Vol. 22, No. 1, 2013, pp. 2-12.
[10] N. Klafke, J. A. Eliott, G. A. Wittert and I. N. Olver, “Prevalence and Predictors of Complementary and Alternative Medicine (CAM) Use by Men in Australian Cancer Outpatient Services,” Annals of Oncology, Vol. 23, No. 6, 2012, pp. 1571-1578. http://dx.doi.org/10.1093/annonc/mdr521
[11] L. C. Lo., C. Y. Chen., S. T. Chen., H. C. Chen., T. C. Lee and C. S. Chang, “Therapeutic Efficacy of Traditional Chinese Medicine, Shen-Mai San, in Cancer Patients Undergoing Chemotherapy or Radiotherapy: Study Protocol for a Randomized, Double-blind, Placebo-Controlled Trial,” Trials, Vol. 13, 2012, p. 232. http://dx.doi.org/10.1186/1745-6215-13-232
[12] I. Cohen, M. Tagliaferri and D. Tripathy, “Traditional Chinese Medicine in the Treatment of Breast Cancer,” Seminars in Oncology, Vol. 29, No. 6, 2002, pp. 563-574. http://dx.doi.org/10.1053/sonc. 2002.50005

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.